Skip to main
IRTC

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies (IRTC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

iRhythm Holdings is a digital healthcare company that provides ambulatory cardiac monitoring services through its Zio System, which combines patch-based biosensors with cloud-based data analytics software. Management expects growth from expanding into the primary care and innovative channel markets, launching its Zio MCT product, and entering into new healthcare categories. Despite concerns around changes to CMS reimbursement criteria, the company saw record volumes and profitability in 2025, leading to strong revenue and EBITDA guidance for 2026. Factors that could drive further upside include higher growth in testing volumes, increased revenue, and growth in international markets. Potential risks include sales execution issues, competition, reimbursement changes, and additional equity offerings.

Bears say

iRhythm Holdings is facing a variety of challenges that could potentially hinder its growth and profitability. Amidst rising competition in the digital healthcare industry, the company's revenue growth has been slowing down and profitability remains low. Its 2026 outlook anticipates only 17-18% revenue growth and a low double-digit EBITDA margin, and with upcoming product launches not expected to have a significant impact on these metrics, the company may struggle to achieve its long-term revenue and profitability goals.

iRhythm Technologies (IRTC) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iRhythm Technologies (IRTC) Forecast

Analysts have given iRhythm Technologies (IRTC) a Buy based on their latest research and market trends.

According to 12 analysts, iRhythm Technologies (IRTC) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $187, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $187, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iRhythm Technologies (IRTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.